Indegene Ltd — earnings calls

At its 28th AGM, Indegene reported FY2025-26 revenue growth of 23.6% to INR35,105 million, crossing INR3,500 crores in annual revenue and INR1,000 crores in a single quarter for the first time. EBITDA grew 11.1% to INR6,247 million while profit after tax was INR4,011 million, with management attributing margin compression to AI investments and integration of its largest acquisition, BioPharm. Management also detailed three completed acquisitions during the year, a reorganization into two segments, and answered shareholder questions on margins, capex, client concentration, and capital allocation.

Indegene reported Q4 FY26 revenue crossing ₹1,000 crores for the first time and full-year FY26 revenue of ₹35,105 million, up 23.6% year-on-year in INR terms and 18.2% in USD terms. Full year adjusted EBITDA was ₹6,793 million, up 20.8% year-on-year, while reported PAT declined 1.4% to ₹4,011 million due to a one-time provision for a US class action lawsuit settlement. Management described several large new deal wins including a Tectonic omnichannel engagement in Germany with its largest customer and a multiyear omnichannel deal exceeding $10 million in ACV.